Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 252Breast Neoplasms 197Glioblastoma 196Lung Neoplasms 195Head and Neck Neoplasms 176Squamous Cell Carcinoma of Head and Neck 166Prostatic Neoplasms 164Lymphoma 152Rectal Neoplasms 132Central Nervous System Neoplasms 119Esophageal Neoplasms 117Leukemia 111Brain Neoplasms 100Pancreatic Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 86Esophageal Squamous Cell Carcinoma 83Lymphoma, Follicular 81Sarcoma 80Lymphoma, Large B-Cell, Diffuse 80Uterine Cervical Neoplasms 76Lymphoma, Non-Hodgkin 75Hodgkin Disease 73Neoplasms 68Burkitt Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Colorectal Neoplasms 63Glioma 61Astrocytoma 60Lymphoma, Large-Cell, Immunoblastic 58

Interventions

Sorafenib 5lenvatinib 2ledipasvir, sofosbuvir drug combination 2halofantrine 2atezolizumab 2Liver Transplantation 2Immunotherapy 2Control Groups 2Blood Specimen Collection 2Bevacizumab 2Antibodies 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1titanium silicide 1sintilimab 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1linifanib 1genexol-PM 1fluorocholine 1fisogatinib 1ficlatuzumab 1durvalumab 1camrelizumab 1belinostat 1bavituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Diseases × Radiotherapy × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡